Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
The Federal Trade Commission (FTC) has approved an application by pharmaceutical company Teva to re-open and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.
The US Court of Appeals for the Federal Circuit has reversed one decision and affirmed another in two cases involving Novartis, with both judgments delivering victory to the Swiss pharmaceutical company.
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
The US Food and Drug Administration has announced a new strategy for the use of “real-world evidence” and “real-world data” to improve its regulation of new drugs.
The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.
The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.
India-based drug company Sun Pharma has made further inroads into the Japanese market with the planned acquisition of Pola Pharma.
The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.